Este archivo ha sido creado el 02.01.2025 por Matilde Durán Lobato GENERAL INFORMATION ------------------ 1. Dataset title: Dataset from Biocompatible gemcitabine-based nanomedicine engineered by Flow Focusing® for efficient antitumor activity. International journal of pharmaceutics, 2013, vol. 443, no 1-2, p. 103-109 (v.0) 2. Authorship: [ Obligatorio | Ponga la información de todos los autores siguiendo el suiguiente formato. Repita el esquema para cada autor.] Lucía Martín-Banderas Universidad de Sevilla Email: luciamartin@us.es ORCID: 0000-0003-1447-6125 Eva Sáez-Fernández Universidad de Granada Email: esaez@ugr.es ORCID: 0000-0002-3669-1291 Mª Ángeles Holgado Universidad de Sevilla Email: holgado@us.es ORCID: 0000-0002-3851-3405 Matilde Durán-Lobato Universidad de Sevilla Email: mduran@us.es ORCID: 0000-0001-5534-6955 José C. Prados Universidad de Granada Email: jcprados@ugr.es ORCID: 0000-0003-0723-3691 Consolación Melguizo Universidad de Granada Email: cmelguizo@ugr.es ORCID: 0000-0002-6742-4230 José L. Arias Universidad de Granada Email: jlarias@ugr.es ORCID: 0000-0002-4953-4298 DESCRIPTION ---------- 1. Dataset language: English 2. Abstract: This dataset corresponds to the article "Biocompatible gemcitabine-based nanomedicine engineered by Flow Focusing® for efficient antitumor activity." It includes experimental data on the preparation and characterization of gemcitabine-loaded PLGA nanoparticles produced by two synthesis methods: double emulsion/solvent evaporation (DE/SEV) and Flow Focusing® (FF). The data encompass zeta potential, drug loading, encapsulation efficiency, drug release profiles and in vitro antitumor activity against MCF-7 cells. 3. Keywords: Antitumor drug; Double emulsion/solvent evaporation; Flow Focusing®; Gemcitabine Nanoparticles; Poly(d,l-lactide-co-glycolide) Antitumoral; Doble-emulsión/evaporación de solvente; Flow Focusing®; Nanopartículas de Gemcitabina; ácido poli(d,l-láctico-co-glicólico) 4. Date of data collection (fecha única o rango de fechas): 01.01.2011 – 01.11.2012 5. Publication Date: 05-01-2013 6. Grant information: [ Obligatorio si aplicable | Financiación recibida. Repita el esquema para cada organismo financiador.] Grant Agency: Instituto de Salud Carlos III Grant Number: FIS 11/02571 Grant Agency: Instituto de Salud Carlos III Grant Number: FIS 11/01862 7. Geographical location/s of data collection: Facultad de Farmacia. Prof García González, 2, 41012 Sevilla, Andalucia, España Campus Reina Mercedes Coordinates: 37°21′39″N 5°59′18″O / 37.36094167, -5.98836111 ACCESS INFORMATION ------------------------ 1. Creative Commons License of the dataset: CC_BY 2. Dataset DOI: 3. Related publication: Martín-Banderas L, Sáez-Fernández E, Holgado MÁ, Durán-Lobato MM, Prados JC, Melguizo C, Arias JL. Biocompatible gemcitabine-based nanomedicine engineered by Flow Focusing for efficient antitumor activity. Int J Pharm. 2013 Feb 25;443(1-2):103-9. doi: 10.1016/j.ijpharm.2012.12.048. Epub 2013 Jan 5. PMID: 23299085. 4. Link to related datasets: VERSIONING AND PROVENANCE --------------- 1. Last modification date: 12-01-2025 2. Were data derived from another source?: NO 3. Additional related data not included in this dataset: METHODOLOGICAL INFORMATION ----------------------- 1. Description of the methods used to collect and generate the data: The dataset includes data from the synthesis and characterization of gemcitabine-loaded PLGA nanoparticles (NPs) produced by two methods: double emulsion/solvent evaporation (DE/SEV) and Flow Focusing® (FF). Zeta potential was determined by electrophoretic mobility measurements with a Malvern Autosizer® 4700. Drug release studies were conducted in vitro using a dialysis method, with UV–Vis spectrophotometry employed to monitor gemcitabine release at 269 nm. Cytotoxicity assays were performed on MCF-7 cells using MTT tests, with absorbance measured at 570 nm using a Tecan Infinite M200 microplate reader. 2. Data processing methods: SPSS was used for statistical analyses, including Student’s t-test to assess significant differences (p < 0.05). Drug quantification was performed via validated UV spectrophotometry at 269 nm, and cytotoxicity data were analyzed using normalized absorbance values. 3. Software or instruments needed to interpret the data: N/A 4. Information about instruments, calibration and standards: Nanoparticle Formulation: Nanoparticles were synthesized using an Ultra-Turrax T25 (IKA, Germany) for DE/SEV and a Flow Focusing® atomizer (Ingeniatrics, Spain) for FF. Physicochemical Characterization: Size and Zeta Potential: Particle size and PDI were determined by dynamic light scattering (DLS), while zeta potential was measured by electrophoretic mobility using a Malvern Autosizer® 4700 (Malvern Instruments, UK), calibrated with polystyrene latex standards. Drug Encapsulation and Release Studies: Encapsulation efficiency and drug loading were quantified by UV spectrophotometry at 269 nm. Drug release was evaluated using the dialysis bag method. Nanoparticles were suspended in phosphate buffer (pH 7.4) and maintained at 37 °C under constant stirring in a Unitronic Vaivén orbital shaker (Selecta S.A., Barcelona, Spain). Samples were collected at predefined time intervals, and drug concentrations were measured by UV spectrophotometry using a Cary Eclipse spectrophotometer (Agilent Technologies, USA). Cytotoxicity Assays: Cytotoxicity was evaluated on MCF-7 human breast cancer cells using the MTT assay. Cells were seeded into 96-well plates at a density of 5,000 cells per well and incubated for 24 hours to allow attachment. Free gemcitabine or NPs containing equal concentrations of gemcitabine were added, and cells were incubated for 24 and 48 hours. After treatment, 20 µL of MTT reagent (5 mg/mL) was added to each well, followed by incubation for 4 hours to allow for the formation of formazan crystals. The medium was carefully removed, and 100 µL of dimethyl sulfoxide (DMSO) was added to dissolve the crystals. Absorbance was measured at 570 nm using a Tecan Infinite M200 microplate reader (Tecan Group Ltd., Switzerland). Cell viability was calculated relative to untreated controls. 5. Environmental or experimental conditions: N/A 6. Quality-assurance procedures performed on the data: [Opcional] FILE OVERVIEW ---------------------- [Se han de mencionar todos los archivos incluidos en el conjunto de datos, con el nombre y la extensión (.csv, .pdf, etc.) de cada archivo. Incluya la estructura de directorios]. 1. Explain the file naming conversion, si es aplicable: A single Excel file with each sheet collecting the data corresponding to a figure or table: -Figure 3: Data corresponding to manuscript Figure 3 on NPs encapsulation efficiency and gemcitabine loading obtained with both methodologies using different values of initial loading. -Figure 4: Data corresponding to manuscript Figure 4 on the zeta potential of NPs produced with both methodologies under different pH values. -Figure 5: Data corresponding to manuscript Figure 5 on the drug release profiles from NPs elaborated with both methodologies. -Figure 6: Data corresponding to manuscript Figure 6 on the cytotoxic effect on MCF-7 human breast adenocarcinoma cells of free gemcitabine, blank and gemcitabine-loaded NPs produced with both methodologies. 2. File list: File name: Dataset from Biocompatible gemcitabine-based nanomedicine engineered by Flow Focusing® for efficient antitumor activity. Description: A single Excel file with each sheet collecting the data corresponding to a figure or table: -Figure 3: Data corresponding to manuscript Figure 3 on NPs encapsulation efficiency and gemcitabine loading obtained with both methodologies using different values of initial loading. -Figure 4: Data corresponding to manuscript Figure 4 on the zeta potential of NPs produced with both methodologies under different pH values. -Figure 5: Data corresponding to manuscript Figure 5 on the drug release profiles from NPs elaborated with both methodologies. -Figure 6: Data corresponding to manuscript Figure 6 on the cytotoxic effect on MCF-7 human breast adenocarcinoma cells of free gemcitabine, blank and gemcitabine-loaded NPs produced with both methodologies. 3. Relationship between files: [ Obligatorio si es aplicable | Relación entre los archivos] 4. File format: Excel 5. If the dataset includes multiple files, specify the directory structure and relationships between the files: [ Obligatorio si es aplicable | Si el conjunto de datos incluye varios archivos, indique la estructura de directorios y las relaciones entre los archivos] SPECIFIC INFORMATION FOR TABULAR DATA ------------------------------------------- [Este apartado se debe repetir para cada archivo de datos que requiera la explicación de variables (habitualmente datos tabulados). Se describirán todas las variables, incluyendo las unidades de medida.] 1. Name file: [Opcional | Nombre del archivo] 2. Number of rows and columns: [Opcional |Número de filas y columnas] 3. Variables list: [Opcional | Repita la estructura para cada variable.] Variable name: Description: Units of measure or value labels | Unidades de medida o etiquetas de valor: 4. Codes or symbols for missing data: [Opcional | Repita la estructura para cada código o símbolo que faltan] Code or symbol: Definition: 5. Special formats or abbreviations used: [Opcional |Formatos especiales o abreviaturas utilizadas] MORE INFORMATION -------------- [Include any other information about the dataset that is not reflected in this template and that you consider relevant. Incluya cualquier otra información sobre el conjunto de datos que no haya quedado reflejada en esta plantilla y que considere relevante]